The management of asthma in the community involves patient education to avoid the triggers, doubling the dose of inhaled steroids and increasing the use of rescue medications during an exacerbation in order to prevent unnecessary hospital visits. This randomized, controlled study looks at whether doubling the dose of inhaled corticosteroid in isolation is effective when asthma deteriorates. (more…)
This study was similar to the study of Harrison and colleagues, which looked at doubling the dose of inhaled corticosteroid dur ...
The guidelines for asthma management recommend the use of regular inhaled corticosteroid in patients with mild persistent asthma, b ...
The role of oral and inhaled corticosteroids in the management of acute asthma is well known. This study compared the effects of in ...
For most patients, asthma is not controlled as defined by guidelines; whether this is achievable has not been prospectively stu ...
Patients with severe persistent asthma who are inadequately controlled despite Global Initiative for Asthma (GINA) 2002 step 4 ther ...
Specific immunotherapy has been widely used to treat allergic rhinitis symptoms. As with any other form of specific immunotherapy, careful patient selection is crucial. The diagnosis of allergic rhinitis needs to be secure, especially in those with perennial symptoms, and should be based on a careful clinical history supported by documentation of IgE-mediated sensitivity by skin prick test or blood tests. (more…)
About twenty percent of patients who have common allergic rhinitis are also having perennial allergic rhinitis symptoms. This f ...
Allergen-specific immunotherapy aims to correct the underlying immune imbalance associated with specific immunotherapy allergic rhi ...
Allergic rhinitis is a very common problem associated with poor quality of life, reductions in social and work activities and p ...
It is now almost a century since the pioneering work of Noon and Freeman was used to successfully treat hay fever symptoms usin ...
Allergic rhinitis is a high-prevalence disease. This high prevalence translates into a high cost to society in terms of overall ...
Roflumilast is an oral, once-daily PDE4 inhibitor with antiinflammatory activity in development for the treatment of asthma. Roflumilast was compared with inhaled beclomethasone dipropionate in patients with asthma.
Once-daily, oral roflumilast 500 µg was comparable with inhaled twice-daily beclomethasone dipropionate (400 µg/day) in improving pulmonary function and asthma symptoms, and reducing the use of rescue medication in patients with asthma. (more…)
Treating allergic rhinitis may have a downstream effect on concomitant asthma and this may be due to attenuation of the underlying ...
Roflumilast is an oral, once-daily inhibitor of phosphodiesterase type 4 (PDE4) that prevents the breakdown of cyclic adenosine ...
Despite optimum drug delivery and good compliance with inhaled corticosteroids, many patients experience symptoms and exacerbat ...
The guidelines for asthma management recommend the use of regular inhaled corticosteroid in patients with mild persistent asthma, b ...
For most patients, asthma is not controlled as defined by guidelines; whether this is achievable has not been prospectively stu ...